**Core tip:** Vascular lakes that resemble extravasation within hepatocellular carcinomas occasionally emerge during chemoembolization. To date, the drainage routes from vascular lakes are not well understood. We present a patient with a recurrent large hepatocellular carcinoma in which a vascular lake emerged during conventional chemoembolization, draining into systemic veins and causing pulmonary and cerebral lipiodol embolism.

INTRODUCTION
============

Transcatheter arterial chemoembolization (TACE) is utilized worldwide for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Although various complications of TACE have been reported\[[@B1]\], cerebral lipiodol embolism (CLE) after TACE is very rare. To our knowledge, 27 cases have been reported in the English literature, and possible pathways for carrying lipiodol from HCCs to systemic arteries have been hypothesized\[[@B2]-[@B18]\]. This is the first report of CLE, in which the vascular lake phenomenon emerged during the TACE procedure and caused an intratumoral arteriovenous shunt, playing the most important role in its occurrence. We also discussed the mechanism of CLE and technical considerations to avoid this serious complication. We also provided a review of the literature.

CASE REPORT
===========

A 63-year-old man with a large recurrent HCC replacing most of the lateral segment of the liver and expanding to the left diaphragm was admitted to our hospital for a second TACE. He had a history of type-B cirrhosis for 3 years. Eight months prior to admission, he had undergone TACE for the same lesion *via* the left hepatic artery (LHA), and the postprocedural course was uneventful. Laboratory tests before second TACE revealed a serum total bilirubin level of 1.4 mg/dL, serum albumin level of 3.0 mg/dL, and prothrombin activity level of 81%. Neither ascites nor hepatic encephalopathy were found, which corresponded to Child-Pugh class A. The α-fetoprotein level was 900 ng/mL. At angiography, the large HCC was supplied by the LHA and the left inferior phrenic artery (LIPA) (Figure [1A](#F1){ref-type="fig"}) without an apparent arteriovenous (AV) shunt. For arterial redistribution to convert multiple feeding arteries into a single arterial supply, distal branches of the LIPA supplying HCC were embolized initially. To avoid migration of embolic materials into pulmonary vessels, the LIPA was embolized with 0.6 mL of a 33% mixture of n-butyl cyanoacrylate (Histoacryl; B. Braun, Melsungen, Germany) and lipiodol (Lipiodol; Terumo Corporation, Tokyo, Japan) (Figure [1B](#F1){ref-type="fig"}). Subsequently, we infused 140 mg of miriplatin (Miripla; Dainippon Sumitomo Pharma, Osaka, Japan) suspended in 7 mL of lipiodol *via* the LHA (Figure [2A](#F2){ref-type="fig"}). This was followed by the injection of 1-mm-diameter gelatin sponge particles (Gelpart; Nippon Kayaku Co. Ltd., Tokyo, Japan). However, the flow of the LHA did not slow down. A repeated left hepatic angiography showed contrast material pooling associated with an aberrant intratumoral space newly developed during embolization, called the "vascular lake phenomenon" (Figure [2B](#F2){ref-type="fig"}). Late-phase imaging revealed that the pericardiacophrenic vein was the draining vein (Figure [2C](#F2){ref-type="fig"}), which was not recognized at the time of the procedure but rather retrospectively after remasking and pixel shifting were performed. Epirubicin (10 mg) (Farmorubicin; Kyowa Hakko, Tokyo, Japan) emulsified in 9 mL of lipiodol was additionally infused into the LHA, followed by the injection of a 2-mm block gelatin sponge (Spongel; Astellas, Tokyo, Japan) until the flow slowed down. Immediately after TACE, the patient became drowsy and disoriented. Unenhanced CT of the brain obtained 30 minutes after the procedure revealed multiple lesions of increased attenuation in the cerebral cortex, basal ganglia, thalami and cerebellum (Figure [3](#F3){ref-type="fig"}). Simultaneously, a CT of the chest revealed hyperattenuation at both lung bases (Figure [4](#F4){ref-type="fig"}). The patient's oxygen saturation was 88%, indicating hypoxia. The patient was monitored in our intensive care unit on mechanical ventilator support. Echocardiography revealed no atrial septal defect or other intracardiac shunts. The patient's level of consciousness gradually improved, but his limb weakness persisted. He was discharged 8 wk later requiring the use of a wheelchair and assistance to eat meals.

![Angiography. A: Selective angiography of the left inferior phrenic artery shows feeding of the anterior part of the tumor without a shunt to the pulmonary vasculature; B: Angiography during glue embolization shows no influx into the pulmonary vasculature.](WJG-24-4291-g001){#F1}

![Infused 140 mg of miriplatin suspended in 7 mL of lipiodol *via* the left hepatic artery. A: Left hepatic angiography shows a large hypervascular tumor in the left hepatic lobe and intrahepatic metastases neighborhood without an intratumoral AV shunt; B: Repeated left hepatic angiography shows a vascular lake in the superior portion of the tumor (arrow) that developed after chemoembolization; C: Venous phase shows drainage into the pericardiacophrenic vein (arrow heads), which was unrecognized until remasking and pixel shifting were performed. AV: Arteriovenous.](WJG-24-4291-g002){#F2}

![Non-contrast brain computed tomography scan obtained 30 min after chemoembolization shows multiple increased attenuated lesions in the bilateral cerebral hemisphere, consistent with lipiodol embolism.](WJG-24-4291-g003){#F3}

![Chest computed tomography scan obtained 30 min after chemoembolization shows lipiodol deposition at both lung bases.](WJG-24-4291-g004){#F4}

DISCUSSION
==========

TACE has been widely accepted as an effective therapy for HCC. Lipiodol is the most common embolic material used in TACE; it is usually mixed with anticancer drugs dissolved in non-ionic contrast medium. Lipiodol can enter the microcirculation of the tumor and flow into the surrounding portal vein, which is the main drainage route from the hypervascular HCC\[[@B19]\]. However, lipiodol can reportedly flow into systemic circulation, causing pulmonary embolism and, rarely, cerebral embolism. We found 27 reports of CLE following TACE in 17 English studies (Table [1](#T1){ref-type="table"}). To reach the cerebral arteries, lipiodol must pass through two pathways, one from the tumor to the pulmonary artery (PA) and the other from the pulmonary artery to the left atrium (LA). Lipiodol accumulation in the lung was identified simultaneously in 17 of 27 previously reported cases\[[@B2]-[@B4],[@B6],[@B8]-[@B10],[@B14],[@B16],[@B18]\].

###### 

Characteristics of 28 cases of cerebral lipiodol embolism

  **Age**   **Sex**   **Tumor characteristics**   **Pulmonary involvement**   **Embolization *via* extrahepatic artery supply**   **Dose of lipiodol**   **AV shunt**   **RL shunt**         **Ref**.
  --------- --------- --------------------------- --------------------------- --------------------------------------------------- ---------------------- -------------- -------------------- --------------
  52        M         Advanced                    \+                          \-                                                  35                                    ND                   \[[@B2]\]
  58        M                                     \+                                                                              8                                     ND                   \[[@B2]\]
  56        M                                     \+                                                                                                                    ND                   \[[@B2]\]
  76        M         Large                       \+                          IPA                                                                                                            \[[@B3]\]
  81        F         Large                       \+                          IPA                                                 20                                    ND                   \[[@B4]\]
  70        F         Large                                                                                                       12                     ND                                  \[[@B5]\]
  62        F         15.0 cm                     \+                          IPA                                                 30                     ND             ND                   \[[@B6]\]
  67        M                                                                 IPA                                                 5                                     PFO                  \[[@B7]\]
  63        F                                                                 IPA                                                 10                                    \+                   \[[@B7]\]
  36        M         Huge                        \+                                                                              40                     ND                                  \[[@B8]\]
  51        F         Huge                        \+                                                                              40                     ND                                  \[[@B9]\]
  41        M         Multiple and PVTT           \+                                                                              30                     \+             ND                   \[[@B10]\]
  71        M                                                                                                                                                           ND                   \[[@B11]\]
  44        M         Large                                                   BA                                                                                                             \[[@B12]\]
  54        M         13.0 cm                                                 IPA                                                 30                                                         \[[@B13]\]
  66        M         11.5 cn                     \+                          \-                                                  4                                     ND                   \[[@B14]\]
  62        M         16.0 cm                                                                                                                                           ND                   \[[@B15]\]
  52        M         18.0 cm                     \+                          IPA                                                 50                     ND             Pulmonary AV shunt   \[[@B16]\]
  66        F                                                                 IPA                                                 20                                                         \[[@B17]\]
  39        M         8.0 cm                                                  IPA                                                 13                     PV                                  \[[@B18]\]
  51        M         13.0 cm                     \+                          \-                                                  30                     PV                                  \[[@B18]\]
  73        F         19.0 cm                     \+                          IPA                                                 15                     PV                                  \[[@B18]\]
  67        F         6.0 cm                      \+                          LGA                                                 10                                                         \[[@B18]\]
  54        F         3.0 cm                                                  IPA                                                 90                                                         \[[@B18]\]
  63        M         14.0 cm                     \+                          RSGA                                                50                                                         \[[@B18]\]
  52        M         17.0 cm                     \+                          \-                                                  30                                                         \[[@B18]\]
  72        M         10.0 cm                     \+                          \-                                                  20                                                         \[[@B18]\]
  63        M         9.0 cm                      \+                          IPA                                                 16                     \+             ND                   Present case

ND: Not detected; IPA: Inferior phrenic artery; AV: Arteriovenous; RL: Right-to-left; PFO: Patent foramen ovale; PVTT: Portal vein tumor thrombus; BA: Bronchial artery; PV: Shunt to pulmonary vein; LGA: Left gastric artery; RSGA: Right superior gluteal artery.

Localized pooling of the contrast medium emerges occasionally during chemoembolization using drug eluting beads (DEB-TACE), resembling extravasation within the tumor. This angiographic finding is known as the vascular lake phenomenon (VLP). As we reported herein, this phenomenon may also appear during chemoembolization using lipiodol, although it is difficult to distinguish a vascular lake from lipiodol accumulating in the tumor by fluoroscopy. Concerning the etiology of VLP during chemoembolization, Seki et al\[[@B20]\] speculated that rapid occlusion of most of the tumor vessels increased the pressure inside the fragile tumor microvasculature, causing disruption of the tumor architecture and a new blood space. VLP is thought to indicate a good local response in HCC patients undergoing DEB-TACE\[[@B20],[@B21]\]. Nevertheless, the drainage routes from vascular lakes are unknown. To the best of our knowledge, this is the first report observing a vascular lake draining into systemic veins, resulting in an intratumoral AV shunt and affording lipiodol pathways to pulmonary vessels.

Intratumoral AV shunts can be the pathway to pulmonary vessels\[[@B5],[@B7],[@B10]\], and this was confirmed by angiography in only one CLE case\[[@B10]\]. On hepatic arteriography, the incidence of intratumoral AV shunts was reported to be 2.4%\[[@B22]\]. According to one study using technetium-99-m-labeled macroaggregated albumin\[[@B23]\], lung shunt fractions exceeding 10% were identified in 50 of 125 HCC patients (40%). The study also reported a direct correlation between angiographic tumor vascularity and lung shunt fractions\[[@B23]\]. The particles of lipiodol emulsion were less than 30 μm in size\[[@B24]\], within the range of the size of technetium-99-m-labeled macroaggregated albumin (10-60 μm in size). Lipiodol redistribution in the lungs may be more frequent than that previously thought.

TACE *via* IPA frequently results in pulmonary complications due to the existence of an AV shunt between the IPA and PA\[[@B25]\]. Some authors speculated that communication between the IPA and pulmonary vessels *via* adhesive pleurae or tumor invasion is the most likely pathway from the tumor to the PA\[[@B4],[@B6]\]. In the present case, we performed IPA embolization using glue under DSA guidance, and the glue fragment never flowed into the pulmonary vessels.

In most previously reported cases of CLE, including the case described herein, a large dose of lipiodol was infused (Table [1](#T1){ref-type="table"}). Cerebral and pulmonary lipiodol embolisms have been reported in patients receiving more than 20 mL of iodized oil after TACE of HCC\[[@B4],[@B6],[@B16],[@B18]\]. According to Kishi et al\[[@B26]\], when lipiodol was infused into the dog's hepatic artery, the amount of lipiodol oil deposition in the lungs was proportional to the lipiodol dose infused. They also found lipiodol deposits in the brain and pancreas\[[@B26]\]. These findings suggested a dose-dependent circulation of oil droplets *via* hepatic sinusoids to pulmonary capillaries and then into the systemic circulation. It was suggested that the lipiodol dose should not exceed 15-20 mL to prevent the risk of an extrahepatic embolism\[[@B4],[@B6]\]. Nevertheless, in 7 previous cases, CLE occurred when the lipiodol dose was \< 15 mL\[[@B2],[@B5],[@B7],[@B14],[@B18]\]. The required lipiodol dose was determined by multiple factors, including the blood supply to the tumor, tumor size, catheter position and liver function reserve. When lipiodol goes through an intratumoral AV shunt, the dose of lipiodol required to accomplish HCC flow stasis increases. If there had not been an intratumoral AV shunt in the presented case, we could have accomplished flow stoppage with a lower dose of lipiodol.

CLE is thought to be associated with intrapulmonary or intracardiac shunts\[[@B4],[@B7],[@B10],[@B16]\]. Evidence of an underlying intracardiac right-to-left shunt was proven by transesophageal echocardiogram in one previous case\[[@B7]\]; however, the pathway from the PA to the LA was not verified in most previously reported cases of CLE, including the present case. Wu et al\[[@B9]\] speculated that an intra-pulmonary arteriovenous shunt might appear during pulmonary lipiodol embolization due to increasing pulmonary artery pressure or hypoxia. Wu et al\[[@B10]\] added that communication between the systemic and pulmonary vessels might develop *via* adhesive pleurae or tumor invasion of the diaphragm, leading to a right-to-left shunt. In a case report of delayed CLE, Wu et al\[[@B8]\] concluded that the rapid flow of the feeding artery washed out the lipiodol, and the lipiodol deposited in the lungs was washed out again upon entering the systemic circulation. Since it has been verified that fat globules \< 7 μm in diameter can pass directly through the pulmonary arteriolar network\[[@B2]\], lipiodol can enter the systemic circulation in the absence of a right-to-left shunt to cause cerebrovascular complications.

In summary, we presented a case in which a vascular lake draining into systemic veins caused a lipiodol cerebral embolism. As intratumoral AV shunts *via* vascular lakes may develop during chemoembolization, we recommend performing repeated angiography during TACE procedures, especially when obtaining a decreased blood flow is difficult. When an intratumoral AV shunt is identified by angiography, embolization of the feeding artery using coils or glue should be considered instead of an additional injection of lipiodol or embolic particles. We should try to prevent lipiodol accumulation in the lungs because the pathways from the PA to the LA cannot be blocked regardless of the mechanism by which they are developed.

ARTICLE HIGHLIGHTS
==================

Case characteristics
--------------------

A 63-year-old man with a large hepatocellular carcinoma underwent transcatheter arterial chemoembolization (TACE), but his level of consciousness deteriorated immediately after the procedure.

Clinical diagnosis
------------------

CT scan of the brain revealed multiple lesions of increased attenuation, and cerebral lipiodol embolism (CLE) was confirmed.

Differential diagnosis
----------------------

There is no differential diagnosis.

Laboratory diagnosis
--------------------

No specific finding was obtained by laboratory testing.

Imaging diagnosis
-----------------

An angiography during TACE procedure revealed a newly developed vascular lake draining into systemic veins, which offered a pathway carrying lipiodol to pulmonary vessels and was the most likely cause of this serious complication.

Pathological diagnosis
----------------------

No pathological examination was performed.

Treatment
---------

The patient was treated in our intensive care unit.

Related reports
---------------

This is the first report of CLE, in which vascular lake phenomenon emerging during the procedure caused intratumoral arteriovenous shunt and played the most important role for its occurrence.

Term explanation
----------------

The term CLE describes cerebral lipiodol embolism.

Experiences and lessons
-----------------------

Arteriovenous shunt *via* vascular lake may develop during chemoembolization, repeated angiography during TACE procedures should be performed to prevent CLE, especially when it is difficult to obtain a decrease of blood flow.
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